Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan

被引:13
|
作者
Negredo, Eugenia [1 ]
Bonjoch, Anna [1 ]
Gomez-Mateu, Moises [2 ]
Estany, Carla [1 ]
Puig, Jordi [1 ]
Perez-Alvarez, Nuria [1 ,2 ]
Rosales, Joaquin [3 ]
di Gregorio, Silvana [3 ]
del Rio, Luis [3 ]
Gomez, Guadalupe [2 ]
Clotet, Bonaventura [1 ,4 ]
机构
[1] Univ Autonoma Barcelona, Lluita SIDA Fdn, Hosp Univ Germans Trias & Pujol, E-08193 Barcelona, Spain
[2] Univ Politecn Cataluna, Stat & Operat Res Dept, Barcelona, Spain
[3] CETIR Ctr Med, Barcelona, Spain
[4] Irsicaixa Fdn, Barcelona, Spain
来源
PLOS ONE | 2012年 / 7卷 / 10期
关键词
BONE-MINERAL DENSITY; ANTIRETROVIRAL THERAPY; PROTEASE INHIBITORS; HIGH PREVALENCE; FRACTURE RISK; OSTEOPOROSIS; WOMEN; DISEASE; OSTEOCLASTOGENESIS; OSTEOBLASTS;
D O I
10.1371/journal.pone.0046031
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Algorithms for bone mineral density (BMD) management in HIV-infected patients are lacking. Our objective was to assess how often a dual-energy x-ray absorptiometry (DXA) scan should be performed by assessing time of progression to osteopenia/osteoporosis. Methods: All DXA scans performed between 2000 and 2009 from HIV-infected patients with at least two DXA were included. Time to an event (osteopenia and osteoporosis) was assessed using the Kaplan-Meier method. Strata (tertiles) were defined using baseline minimum T scores. Differences between strata in time to an event were compared with the log-rank test. Results: Of 391 patients (1,639 DXAs), 49.6% had osteopenia and 21.7% osteoporosis at their first DXA scan. Of the 112 (28.6%) with normal BMD, 35.7% progressed to osteopenia; median progression time was 6.7 years. These patients were stratified: "low-risk" (baseline minimum T score > -0.2 SD), "middle-risk" (between -0.2 and -0.6 SD), and "high-risk" (from -0.6 to -1 SD); median progression time to osteopenia was 8.7, >7.2, and 1.7 years, respectively (p<0.0001). Of patients with osteopenia, 23.7% progressed to osteoporosis; median progression time was >8.5 years. Progression time was >8.2 years in "low-risk" tertile (T score between -1.1 and -1.6 SD), >8.5 years in "middle-risk" (between -1.6 and -2), and 3.2 years in "high-risk" (from -2 to -2.4) (p<0.0001). Conclusions: Our results may help to define the BMD testing interval. The lowest T score tertiles would suggest recommending a subsequent DXA in 1-2 years; in the highest tertiles, >= 6 years. Early intervention in patients with bone demineralization could reduce fracture-related morbidity/mortality.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Osteopenia and osteoporosis in HIV-infected patients
    Golaszewska, Dorota
    Racewicz, Artur
    [J]. HIV & AIDS REVIEW, 2007, 6 (03): : 5 - 9
  • [2] Osteopenia/osteoporosis in highly-experienced HIV-infected patients
    Seminari, E
    Galli, L
    Rubinacci, A
    Galli, A
    Fusetti, G
    Soldarini, A
    Castagna, A
    [J]. ANTIVIRAL THERAPY, 2003, 8 (04) : L95 - L95
  • [3] Osteopenia, Osteoporosis, and Fractures in HIV-Infected Patients: Extent of the Problem
    Harris, V. Walker
    Brown, T. T.
    [J]. CLINICAL REVIEWS IN BONE AND MINERAL METABOLISM, 2012, 10 (04): : 246 - 256
  • [4] Osteopenia, Osteoporosis, and Fractures in HIV-Infected Patients: Extent of the Problem
    V. Walker Harris
    T. T. Brown
    [J]. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10 (4): : 246 - 256
  • [5] Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients
    Konishi, M
    Takahashi, K
    Yoshimoto, E
    Uno, K
    Kasahara, K
    Mikasa, K
    [J]. AIDS, 2005, 19 (11) : 1240 - 1241
  • [6] Osteopenia and lipodistrophy in HIV-infected patients
    Azriel, S.
    Rubio, R.
    Requejo, H.
    Guadalix, S.
    Jodar, E.
    Martinez, G.
    Hawkins, F.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S224 - S224
  • [7] Valid treatment options for osteoporosis and osteopenia in HIV-infected persons
    Clay, Patrick G.
    Voss, Laura E.
    Williams, Charlott
    Daume, Eric C.
    [J]. ANNALS OF PHARMACOTHERAPY, 2008, 42 (05) : 670 - 679
  • [8] Osteoporosis in HIV-infected patients
    Groger R.
    Quirk E.
    Powderly W.G.
    [J]. Clinical Reviews in Bone and Mineral Metabolism, 2004, 2 (2): : 167 - 173
  • [9] Osteopenia in HIV-infected patients:: is it the disease or is it the treatment?
    Knobel, H
    Guelar, A
    Vallecillo, G
    Nogués, X
    Díez, A
    [J]. AIDS, 2001, 15 (06) : 807 - 808
  • [10] Association between osteopenia/osteoporosis and RANK/RANKL/OPG system in HIV-infected patients
    D'Abramo, A.
    D'Agostino, C.
    Iannetta, M.
    Erario, L.
    Massetti, A. P.
    Vullo, V.
    [J]. INFECTION, 2010, 38 : 44 - 44